-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the improvement of people's living standards, increased investment in public health, and the increasing degree of population aging, the pharmaceutical market has developed rapidly in China
According to the data released by the National Bureau of Statistics on July 27, in the first half of 2021, the national pharmaceutical manufacturing industry achieved a year-on-year increase of 28.
In addition, according to the semi-annual report data released by major companies, many companies have ushered in gratifying results
According to the report, in the first half of 2021, Harbin Pharmaceutical Group's operating income increased by 33.
On August 16, Lifang Pharmaceutical also disclosed its semi-annual report.
On the same day (August 16th), Neptunus Biology also issued a semi-annual report stating that its operating income in the first half of 2021 increased by 13.
In addition, in terms of Chinese medicine companies, many companies also submitted satisfactory answers in the first half of the year
Some analysts pointed out that with the maturity of the domestic pharmaceutical industry environment, domestic pharmaceutical companies have set off an upsurge of innovation.
In addition, according to the research and development progress of the research project announced by Betta Pharmaceuticals, its first-line treatment of ALK-positive NSCLC patients with Ensatinib hydrochloride is already in the Pre-NDA stage in the United States and will be declared for marketing in the United States in 2021; multi-target RTKs inhibitor CM082 The indication for the treatment of metastatic renal cell carcinoma that has failed the previous VEGFR-TKI first-line treatment is currently in clinical II/III, and a marketing application will be submitted in China this year
In addition, in the first half of this year, the total R&D investment of Enhua Pharmaceuticals and Mike Biology exceeded 100 million yuan, 157 million yuan and 111 million yuan respectively; the total R&D investment of Yuandong Biology, Aide Biology, and Weiss Medical accounted for the proportion of revenue.
